Celgene International SA rl, a wholly-owned subsidiary of Celgene Corporation , today announced data from a study comparing melphalan, prednisone and REVLIMID with high-dose chemotherapy and tandem autologous stem cell transplant , as well as evaluating the effect of lenalidomide maintenance in patients with newly-diagnosed multiple myeloma were ... (more)
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130603005898&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130603005898&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment